With an improved median survival of 6.2 years, lung transplantation has become an
increasingly acceptable treatment option for end-stage lung disease. Besides survival …

Lung transplantation is a life-saving treatment for patients with end stage lung disease. The
imbalance between lung graft supply and recipients has been a serious issue and barrier to …

Background Donor lung use for transplantation is the lowest among solid organ tranplants
because of several complex and multifactorial reasons; one area that could have a …

Transplantation is the optimal treatment for most patients with end‐stage kidney disease but
organ shortage is a major challenge. Normothermic machine perfusion (NMP) has been …

The number of waitlisted lung transplant candidates exceeds the availability of donor
organs. Barriers to utilization of donor lungs include suboptimal lung allograft function, long …

SARS-CoV-2 has spread across the globe with an astonishing velocity and lethality that has
put scientist and pharmaceutical companies worldwide on the spot to develop novel …

Allogeneic lung transplantation (LuTx) is considered the treatment of choice for a broad
range of advanced, progressive lung diseases resistant to conventional treatment regimens …

Dysfunction of the pulmonary allograft with impaired oxygenation and radiographic opacities
consistent with pulmonary edema occurs in up to 50% of lung transplant (LTx) recipients. 1 …

Background Survival after out-of-hospital cardiac arrest (OHCA) is poor and dependent on
high-quality cardiopulmonary resuscitation. Resuscitative endovascular balloon occlusion of …

Objective Ex vivo lung perfusion (EVLP) is reportedly a useful strategy that permits marginal
donor lungs to be evaluated and reconditioned for successful lung transplantation (LTx) …